Photobiomodulation for Cancer-Related Cognitive Impairment
NCT: NCT05855694 · NOT_YET_RECRUITING
Brief Summary
This is a single site, pilot randomized, double blinded control trial designed to assess changes in cognitive symptoms in cancer survivors with cancer-related cognitive impairment. Patients will be randomized into one of two Arms: Intervention or Control. * Arm A: Intervention Group: Use of the THOR LED Photobiomodulation helmet 3x per week for 6 weeks. Helmet will be in 'therapeutic setting', 35mW/cm2 = 42J/cm2 * Arm B: Control Group: Use of the THOR LED Photobiomodulation helmet 3x per week for 6 weeks. Helmet will be in 'placebo setting', 0mW/cm2 = 0J/cm2 This study has been designed to assess the hypothesis that Photobiomodulation can have a positive impact on cognitive symptoms in cancer survivors with cancer-related cognitive impairment. 30 participants will be recruited for this study, 15 per group. Self-report questionnaires assessing cognitive concerns, cognitive abilities, quality of life, depression, and anxiety will be administered at three timepoints through the study Baseline, End of Study Visit and 1 Month Follow Up
Frequently Asked Questions
What is Photobiomodulation for Cancer-Related Cognitive Impairment?
Photobiomodulation for Cancer-Related Cognitive Impairment is a clinical trial registered under NCT05855694. Current status: NOT_YET_RECRUITING.
What is the status of NCT05855694?
The current status of NCT05855694 (Photobiomodulation for Cancer-Related Cognitive Impairment) is: NOT_YET_RECRUITING.
When did Photobiomodulation for Cancer-Related Cognitive Impairment start?
Photobiomodulation for Cancer-Related Cognitive Impairment started on 2026-06.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.